One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
ESMO pays tribute to Professor José Baselga
S.Peters1J.Tabernero2A.Cervantes3S.Banerjee4R.Giuliani5F.Lordick6
Building bridges between drug development and cancer science: a tribute to José Baselga's legacy
D.M.Hyman1J.-C.Soria23J.Tabernero4
Outcomes of treatment choices in poor prognosis prostate cancer: not against all odds
D.G.J.RobbrechtS.A.J.BuckR.de Wit
How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy
A.Fundytus12C.M.Booth123I.F.Tannock4
Genomic testing for targeted oncology drugs: hopes against hype
R.Dienstmann12D.Tamborero3
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A.-M.C.Dingemans12M.Früh34A.Ardizzoni5B.Besse67C.Faivre-Finn8L.E.Hendriks2S.Lantuejoul9S.Peters10N.Reguart11C.M.Rudin12D.De Ruysscher13P.E.Van Schil14J.Vansteenkiste15M.Reck16ESMO Guidelines Committee
Novel adjuvant options for cutaneous melanoma
F.Dimitriou12G.V.Long134A.M.Menzies134
Immunotherapy use outside clinical trial populations: never say never?
K.Rzeniewicz12J.Larkin3A.M.Menzies45†S.Turajlic23â€
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
D.RodrÃguez-Abreu1S.F.Powell2M.J.Hochmair3S.Gadgeel4†E.Esteban5E.Felip6G.Speranza7F.De Angelis7M.Dómine8S.Y.Cheng9H.G.Bischoff10N.Peled11M.Reck12R.Hui13E.B.Garon14M.Boyer15T.Kurata16J.Yang17…M.C.Garassino1819
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial
M.Annala12S.Fu34J.V.W.Bacon1J.Sipola2N.Iqbal5C.Ferrario6M.Ong7D.Wadhwa8S.J.Hotte9G.Lo10B.Tran11L.A.Wood12J.R.Gingerich13S.A.North14C.J.Pezaro1516J.D.Ruether17S.S.Sridhar18H.M.L.Kallio2…K.N.Chi13â€
Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS–MAPK pathway and TP53 as potential predictors of immunotherapy efficacy
J.Y.Wang12J.Xiu3Y.Baca3H.Arai2F.Battaglin2N.Kawanishi2S.Soni2W.Zhang2J.Millstein4A.F.Shields5A.Grothey6B.A.Weinberg7J.L.Marshall7E.Lou8M.Khushman9D.P.S.Sohal10M.J.Hall11M.Oberley3…H.J.Lenz2
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma
C.N.Owen12X.Bai34T.Quah5S.N.Lo1C.Allayous6S.Callaghan7C.MartÃnez-Vila8R.Wallace9P.Bhave10I.L.M.Reijers11N.Thompson2V.Vanella12C.L.Gerard13S.Aspeslagh14A.Labianca15A.Khattak16M.Mandala17W.Xu18…A.M.Menzies12425â€
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
A.Haslam1M.S.Kim2V.Prasad1
Multidisciplinary tumor boards present technical and financial challenges in the COVID-19 era
B.A.Schroeder1E.Cuevas2J.J.Graber3
Estrogen and COVID-19: friend or foe?
A.Di Vincenzo1A.Andrisani2R.Vettor1M.Rossato1
Checkpoint inhibition: protecting against or predisposing for second primary tumors?
K.P.M.Suijkerbuijk1A.M.May2M.J.M.van Eijs13
Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?
A.Laparra1M.Kfoury2S.Champiat1F.X.Danlos1P.Martin-Romano1A.Simonaggio1C.Baldini1P.Vuagnat1C.Mateus2A.L.Voisin3L.Albiges2B.Besse24C.Even2C.Robert24S.Laghouati3C.Massard14A.Marabelle1O.Lambotte4567J.M.Michot1
Bayesian interpretation of the ESMO guideline for localized colorectal cancer: a better IDEA
A.Carmona-Bayonas1P.Jimenez-Fonseca2V.Valenti3R.Salazar4
VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma
K.S.Tewari1B.J.Monk2I.Vergote3A.Miller4A.C.de Melo5H.S.Kim6Y.M.Kim6A.Lisyanskaya7V.Samouëlian8D.Lorusso9F.Damian10C-L.Chang11E.A.Gotovkin12S.Takahashi13D.Ramone14J.Pikiel15J.Li16M.Mathias16…A.Oaknin17
VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial
R.Soo1J-Y.Han2G.Dimopoulou3B.C.Cho4C.M.Yeo5E.Nadal6E.Carcereny7J.de Castro8M.A.Sala9R.Bernabe10L.Coate11M.Provencio12R. GarciaCampelo13S.Cuffe14S.Hashemi15M.Früh16B.Ruepp17H.Roschitzki-Voser17…S.Peters19
Corrigendum to ‘Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers’: [Annals of Oncology Volume 29, Issue 3, March 2018, Pages 715-723]
G.Fossard123F.Broussais1I.Coelho4S.Bailly56E.Nicolas-Virelizier7E.Toussaint8C.Lancesseur9F.Le Bras10E.Willems11E.Tchernonog12T.Chalopin13R.Delarue14R.Gressin15A.Chauchet16E.Gyan13G.Cartron12C.Bonnet11C.Haioun10…E.Bachy123
